NDAINJECTIONINJECTABLEPriority Review
Approved
May 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Mithracin (plicamycin) is a small-molecule antibiotic injectable approved in 1970 for treating testicular cancer and hypercalcemia of malignancy. It functions as a DNA-intercalating agent that inhibits RNA synthesis in rapidly dividing cells. The drug represents a legacy oncology agent with decades of clinical use in niche indications.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal current commercial momentum, team size and investment are likely lean and declining.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Mithracin offers limited career growth; the product generates zero linked job openings and operates in a shrinking commercial space. Roles are primarily custodial, supporting a declining revenue base with minimal innovation or expansion opportunities.
Product ManagerSales Representative
Worked on MITHRACIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.